Introduction: The Rising Challenge of Pertussis
Pertussis is a highly contagious bacterial infection affecting the respiratory tract, notorious for its severe coughing fits and the distinctive "whoop" sound that follows. While it can affect individuals of any age, infants and young children are particularly vulnerable to severe complications and even death. Recent years have seen a worrying uptick in pertussis cases, with the United States alone reporting 8,485 cases in early 2025—nearly double the number from the previous year. This resurgence is attributed to declining vaccination rates, growing anti-vaccine sentiment, and disruptions in immunization services.
Get More Information : https://www.sphericalinsights.com/our-insights/pertussis-market
Market Overview: Growth and Opportunities
Pertussis Market Size and Forecast
The Global Pertussis Market Size is expected to Grow from USD 3.92 Billion in 2024 to USD 7.04 Billion by 2035, at a CAGR of 5.47% during the forecast period 2025-2035, owing to the launch of new therapies in the market and the rise in the number of cases. This growth is fueled by:
- Increasing disease incidence and outbreaks
- Expanded immunization programs
- Innovations in vaccine formulations and delivery
- Rising awareness of adult and maternal immunization
Understanding Pertussis: Disease Burden and Risks
Pertussis is caused by the bacterium Bordetella pertussis and spreads via respiratory droplets. The disease is especially dangerous for infants, who are at the highest risk of hospitalization and death due to their immature immune systems and inability to receive the vaccine before six weeks of age. Complications can include pneumonia, seizures, encephalopathy, and, in severe cases, death.
Key Symptoms
- Severe, persistent cough with "whoop" sound
- Runny or stuffy nose
- Sneezing and mild fever
- Vomiting after coughing fits
- Difficulty breathing and fatigue
Diagnosis
Diagnosis involves clinical evaluation, medical history, and laboratory testing, including PCR or culture from a nasopharyngeal swab.
Vaccination: The Cornerstone of Pertussis Control
Types of Pertussis Vaccines
There are two main combination vaccines used for pertussis prevention:
- DTaP: For infants and children under 7 years, protects against diphtheria, tetanus, and pertussis.
- Tdap: For older children, adolescents, and adults, with reduced concentrations of pertussis antigen.
CDC and Global Recommendations
Pediatric Immunization Schedule
The Centers for Disease Control and Prevention (CDC) and other health authorities recommend a 5-dose DTaP series for children:
- 2 months
- 4 months
- 6 months
- 15–18 months
- 4–6 years
Adolescent and Adult Immunization
- Adolescents: Single Tdap booster at 11–12 years
- Adults: At least one Tdap booster if not previously received, with a Td or Tdap booster every 10 years
- Pregnant Women: Tdap during every pregnancy (ideally between 27–36 weeks) to protect newborns via maternal antibodies
Catch-Up and Special Populations
- Catch-up vaccination is recommended for children and adults who missed their scheduled doses.
- Close contacts of infants (parents, caregivers, grandparents) are encouraged to receive a Tdap booster to create a protective "cocoon" around vulnerable babies.
Effectiveness and Safety of Pertussis Vaccines
Efficacy
- DTaP: 98% protection after the full five-dose series in the first year; 65% protection five years after the last dose.
- Tdap (Adolescents): 74% effectiveness in teens.
- Tdap (Pregnancy): 91–94% reduction in infant hospitalization due to pertussis.
Safety
- Most common side effects: mild pain, redness, and swelling at the injection site (20–40% of infants), low-grade fever (3–5%).
- Serious adverse events are rare (<1%).
Buy Report : https://www.sphericalinsights.com/checkout-insights/2788
Market Trends: What’s Shaping the Pertussis Landscape in 2025?
1. Resurgence of Disease and Public Health Response
- Rising Incidence: Pertussis cases have surged by 500% in some regions, highlighting the urgent need for improved vaccine coverage.
- Outbreaks: Recent deaths in the US, including infants and adults, underscore the disease’s severity and the gaps in current protection.
2. Expanding Vaccine Recommendations
- Maternal Immunization: Increasing emphasis on vaccinating pregnant women to protect newborns.
- Adult Boosters: Greater focus on adult immunization, especially for those in close contact with infants and high-risk groups.
- Catch-Up Campaigns: Targeted outreach to under-vaccinated populations and those who missed scheduled doses.
3. Addressing Vaccine Hesitancy
- Anti-Vaccine Sentiment: Growing hesitancy, fueled by misinformation, has led to declining coverage and increased outbreaks.
- Public Education: Health authorities are ramping up efforts to educate the public on vaccine safety and the importance of timely immunization.
4. Innovations in Vaccine Formulation and Delivery
- Acellular Vaccines: All pertussis vaccines in use are acellular, reducing the risk of side effects compared to older whole-cell formulations.
- Combination Vaccines: Continued development of vaccines that protect against multiple diseases (e.g., DTaP-IPV-Hib) for streamlined immunization.
- Research into New Boosters: Ongoing studies aim to improve long-term immunity and address waning protection in older children and adults.
5. Global Market Expansion
- Emerging Markets: Increased investment in immunization infrastructure in low- and middle-income countries.
- Government Initiatives: National immunization programs and partnerships with global health organizations are expanding access to pertussis vaccines.
Enhancing Vaccine Coverage: Strategies for 2025
Improving Access and Convenience
- School-Based Vaccination: Implementing vaccination programs in schools to reach adolescents efficiently.
- Pharmacy-Based Immunization: Allowing adults to receive Tdap boosters at pharmacies and community clinics.
Strengthening Surveillance and Outbreak Response
- Enhanced Disease Monitoring: Real-time tracking of pertussis cases to identify outbreaks and target interventions.
- Rapid Response Teams: Mobilizing healthcare workers to affected areas for outbreak containment and vaccination drives.
Leveraging Digital Health and Communication
- Immunization Reminders: Text messages and app notifications to remind families of upcoming vaccine appointments.
- Combatting Misinformation: Social media campaigns and trusted voices to counteract anti-vaccine narratives.
Policy and Funding Initiatives
- Government Subsidies: Reducing out-of-pocket costs for vaccines to encourage uptake.
- Mandates for School Entry: Requiring proof of pertussis vaccination for school enrollment.
Addressing Special Populations: Focus on Vulnerable Groups
Infants and Young Children
- Timely Primary Series: Ensuring infants receive DTaP on schedule to maximize early protection.
- Cocooning Strategy: Vaccinating family members and caregivers to shield infants too young for vaccination.
Pregnant Women
- Routine Tdap in Pregnancy: Strong recommendations for Tdap during every pregnancy, regardless of prior immunization history, for optimal newborn protection.
Adults and Seniors
- Booster Doses: Encouraging regular Tdap boosters, especially for those in close contact with infants or with chronic health conditions.
Overcoming Barriers: Challenges and Solutions
Waning Immunity
- Solution: Research into improved booster schedules and next-generation vaccines to extend protection.
Vaccine Hesitancy
- Solution: Transparent communication about vaccine safety, efficacy, and the risks of pertussis.
Access Inequities
- Solution: Outreach to underserved communities, mobile vaccination units, and integration with other health services.
Conclusion: Securing the Future Against Pertussis
The pertussis market is at a pivotal moment. With disease incidence rising and vaccination rates under pressure, there is an urgent need to enhance both pediatric and adult vaccine coverage. The market is poised for significant growth, driven by expanded recommendations, innovative delivery strategies, and a renewed focus on public education. By prioritizing timely immunization, addressing vaccine hesitancy, and ensuring equitable access, we can protect vulnerable populations and curb the resurgence of this preventable disease.
Healthcare providers, policymakers, and the public must work together to ensure that every child and adult receives the protection they need. As we look to 2025 and beyond, strengthening pertussis immunization programs will be critical to safeguarding global health and preventing future outbreaks.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: [email protected], [email protected]
Contact Us: https://www.sphericalinsights.com/contact-us